ANDA Guidance: Reference Listed Drug Vs. Reference Standard Explained
Executive Summary
US FDA’s Orange Book will clarify which drugs are reference listed drugs for use in demonstrating sameness, and which are reference standards for purposes of in vivo bioequivalence testing.
You may also be interested in...
FDA's Document Dump: Guidance Release Skyrockets Ahead Of Trump's Arrival
Uncertainty about US FDA's direction under the new president may have spurred staff to ensure views on several issues released before administration changed.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.